Chempartner Pharmatech Valuation
Is 300149 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300149 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300149 (CN¥4.67) is trading below our estimate of fair value (CN¥14.15)
Significantly Below Fair Value: 300149 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300149?
Other financial metrics that can be useful for relative valuation.
| What is 300149's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥2.33b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | -47.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 300149's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.5x | ||
300238 Guanhao BiotechLtd | 5.8x | n/a | CN¥2.3b |
000710 Berry GenomicsLtd | 2.1x | n/a | CN¥2.5b |
300313 Xinjiang Tianshan Animal Husbandry Bio-engineering | 15.5x | n/a | CN¥2.1b |
688137 Novoprotein Scientific | 14.5x | n/a | CN¥2.2b |
300149 Chempartner Pharmatech | 2x | n/a | CN¥2.3b |
Price-To-Sales vs Peers: 300149 is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (9.5x).
Price to Earnings Ratio vs Industry
How does 300149's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Sales vs Industry: 300149 is good value based on its Price-To-Sales Ratio (2x) compared to the CN Biotechs industry average (6.6x).
Price to Sales Ratio vs Fair Ratio
What is 300149's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300149's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.